Complementary and alternative medicine research: A National Cancer Institute perspective
- 1 December 2002
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 29 (6) , 546-551
- https://doi.org/10.1053/sonc.2002.50003
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Surveys of Complementary and Alternative Medicine: Part II. Use of Alternative and Complementary Cancer TherapiesThe Journal of Alternative and Complementary Medicine, 2001
- Efficacy of Antineoplastons A10 and AS2-1Mayo Clinic Proceedings, 1999
- Phase I/II Study of Stage III and IV Non-Small Cell Lung Cancer Patients Taking a Specific Dietary SupplementNutrition and Cancer, 1999
- Evaluation of Pancreatic Proteolytic Enzyme Treatment of Adenocarcinoma of the Pancreas, With Nutrition and Detoxification SupportNutrition and Cancer, 1999
- Phase II Study of Antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in Patients With Recurrent GliomaMayo Clinic Proceedings, 1999
- The Use of Complementary Medications by Cancer Patients Attending an Outpatient Pain and Symptom ClinicJournal of Palliative Care, 1998
- The prevalence of complementary/Alternative medicine in cancerCancer, 1998
- Placebo-controlled randomized study of hydrazine sulfate in lung cancer.Journal of Clinical Oncology, 1995
- Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experienceCancer, 1987
- A Clinical Trial of Amygdalin (Laetrile) in the Treatment of Human CancerNew England Journal of Medicine, 1982